| Synonyms: | |
| Status: | Phase 3 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 4N4457MV2U |
| InChI Key | CMSGWTNRGKRWGS-NQIIRXRSSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C26H25F9N2O4 |
| Molecular Weight | 600.48 |
| AlogP | 8.2 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 5.0 |
| Polar Surface Area | 59.08 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 41.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Cholesteryl ester transfer protein inhibitor | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Ion channel
Other ion channel
Pore-forming toxins (proteins and peptides)
|
- | 3-110 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hyperlipidemias | 3 | D006949 | ClinicalTrials |
| Hyperlipoproteinemia Type II | 3 | D006938 | ClinicalTrials |
| Hyperlipoproteinemia Type III | 3 | D006952 | ClinicalTrials |
| Hyperlipidemia, Familial Combined | 3 | D006950 | ClinicalTrials |
| Coronary Disease | 3 | D003327 | ClinicalTrials |
| Hypertriglyceridemia | 3 | D015228 | ClinicalTrials |
| Hypercholesterolemia | 3 | D006937 | ClinicalTrials |
| Lipid Metabolism Disorders | 3 | D052439 | ClinicalTrials |
| Hyperlipoproteinemia Type IV | 3 | D006953 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 262352-17-0 |
| ChEBI | 49203 |
| ChEMBL | CHEMBL479527 |
| DrugBank | DB06281 |
| EPA CompTox | DTXSID20180873 |
| FDA SRS | 4N4457MV2U |
| PDB | 0RP |
| PubChem | 159325 |
| SureChEMBL | SCHEMBL49081 |
| ZINC | ZINC000008214714 |